Hydrazine Sulfate: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Hydrazine sulfate is a hazardous, colorless liquid with an ammonia-like odor. It's used for industrial purposes and sometimes as medicine. It's also unsafe.

Hydrazine sulfate might block certain chemical reactions in the body that can lead to malnutrition and muscle wasting.

People use hydrazine sulfate for cancer, weight loss in people with cancer, and other conditions, but there is no good scientific evidence to support these uses.

Uses & Effectiveness

Possibly Ineffective for

Cancer. Taking hydrazine sulfate by mouth doesn't seem to help treat various types of cancer.

Likely InEffective for

Lung cancer. Adding hydrazine sulfate to chemotherapy does not improve quality of life or survival in most people with non-small cell lung cancer.

There is interest in using hydrazine sulfate for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Side Effects

When taken by mouth: Hydrazine sulfate is possibly unsafe. It has been linked to cases of liver damage, seizure, coma, and death.

Special Precautions and Warnings

When taken by mouth: Hydrazine sulfate is possibly unsafe. It has been linked to cases of liver damage, seizure, coma, and death.

Pregnancy and breast-feeding: Hydrazine sulfate is possibly unsafe for anyone, including those who are pregnant and breast-feeding. It has been linked to cases of liver damage, seizure, coma, and death.

Liver disease: Hydrazine sulfate might damage the liver. Taking hydrazine sulfate might make liver disease worse.

Surgery: Hydrazine sulfate might affect blood sugar control during and after surgery. Stop using hydrazine sulfate at least 2 weeks before a scheduled surgery.

Interactions

Moderate Interaction

Be cautious with this combination

Isoniazid interacts with Hydrazine Sulfate
Isoniazid can cause liver damage in some people. Hydrazine sulfate can also cause liver damage. Using both isoniazid and hydrazine sulfate might increase the risk of liver damage.
Medications for depression (MAOIs) interacts with Hydrazine Sulfate
Hydrazine sulfate contains a chemical that affects the body. This chemical might increase the side effects of some medications used for depression.

Some common MAOIs include phenelzine (Nardil), selegiline (Zelapar), and tranylcypromine (Parnate).
Medications for diabetes (Antidiabetes drugs) interacts with Hydrazine Sulfate
Hydrazine sulfate might lower blood sugar levels. Taking hydrazine sulfate along with diabetes medications might cause blood sugar to drop too low. Monitor your blood sugar closely.

Dosing

Hydrazine sulfate has most commonly been used by adults along with chemotherapy. But it can be unsafe. Speak with a healthcare provider before using.

View References

REFERENCES:

Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria [letter]. N Engl J Med 1997;336:1328.

Bouhnik Y, Vahedi K, Achour L, et al. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr 1999;129:113-6.

Loprinzi CL, Goldberg RM, Burnham NL. Cancer-associated anorexia and cachexia. Implications for drug therapy. Drugs 1992;43:499-506.

Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994;12:1126-9.

Loprinzi CL, Kuross SA, O'Fallon JR, et al. Randomized, placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12:1121-5.

Kosty MP, Fleishman SB, Herndon JE II, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized, placebo-controlled, double-blind phase III study of the cancer and leukemia Group B. J Clin Oncol 1994;12:1113-20.

Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. Cancer 1987;59:406-10.

Kaegi E. Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998;158:1327-30.

Hainer MI, Tsai N, Komura ST, Chiu CL. Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 2000;133:877-80.

Gershanovich ML, Danova LA, Ivin BA, Filov VA. Results of clinical study antitumor action of hydrazine sulfate. Nutr Cancer 1981;3:7-12..

Herndon JE 2nd, Fleishman S, Kosty MP, Green MR. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials 1997;18:286-300.

Ochoa M Jr, Wittes RE, Krakoff IH. Trial of hydrazine sulfate (NSC-150014) in patients with cancer. Cancer Chemother Rep 1975;59:1151-4.

Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 1999;289:695-702.

Black M, Hussain H. Hydrazine, cancer, the Internet, isoniazid, and the liver. Ann Intern Med 2000;133:911-3.

Vickers, A. Alternative cancer cures: "unproven" or "disproven"? CA Cancer J Clin 2004;54(2):110-118.

Gershanovich, M. L., Danova, L. A., Kondratyev, V. B., Malyugina, L. L., Stukov, A. N., Seitz, J. F., and Filov, V. A. Clinical data on the antitumor activity of hydrazine sulfate. Cancer Treat.Rep. 1976;60(7):933-935.

Lerner, H. J. and Regelson, W. Clinical trial of hydrazine sulfate in solid tumors. Cancer Treat.Rep. 1976;60(7):959-960.

Nagappan, R. and Riddell, T. Pyridoxine therapy in a patient with severe hydrazine sulfate toxicity. Crit Care Med. 2000;28(6):2116-2118.

Grubbs, B., Rogers, W., and Cameron, I. Total parenteral nutrition and inhibition of gluconeogenesis on tumor- host responses. Oncology 1979;36(5):216-223.

Wiernikowski, A. and Langer, D. [Acute poisoning with orally ingested hydrazine hydrate]. Polski Tygodnik Lekarski 7-21-1975;30(29):1231-1232.

Gold, J. Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. Oncology 1975;32(1):1-10.

Bruera, E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49 Suppl 2:35-42.

Chlebowski, R. T., Bulcavage, L., Grosvenor, M., Oktay, E., Block, J. B., Chlebowski, J. S., Ali, I., and Elashoff, R. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J.Clin.Oncol. 1990;8(1):9-15.

Tayek, J. A., Heber, D., and Chlebowski, R. T. Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. Lancet 8-1-1987;2(8553):241-244.

Cavaliere, A., Bufalari, A., and Vitali, R. Carcinogenicity and cocarcinogenicity test of phenobarbital sodium in adult BALB/c mice. Tumori 4-30-1986;72(2):125-128.

Bosan, W. S., Shank, R. C., MacEwen, J. D., Gaworski, C. L., and Newberne, P. M. Methylation of DNA guanine during the course of induction of liver cancer in hamsters by hydrazine or dimethylnitrosamine. Carcinogenesis 1987;8(3):439-444.

Spremulli, E., Wampler, G. L., and Regelson, W. Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemother.Pharmacol. 1979;3(2):121-124.

Chlebowski, R. T. Critical evaluation of the role of nutritional support with chemotherapy. Cancer 1-1-1985;55(1 Suppl):268-272.

Laszlo, J., Durant, J., and Loeb, V. Clinical pharmacologic study of 1-acetyl-2-picolinoyl hydrazine (NSC- 68626). Cancer Chemother Rep 1969;53(2):131-134.

Gold, J. Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 1968;22(2):185-207.

Freese, E., Sklarow, S., and Freese, E. B. DNA damage caused by antidepressant hydrazines and related drugs. Mutat.Res 1968;5(3):343-348.

Reid, F. J. Hydrazine poisoning. Br Med J 11-20-1965;5472:1246.

Quintero-Ruiz, A., Paz-Neri, L. L., and Villa-Trevino, S. Indirect alkylation of CBA mouse liver DNA and RNA by hydrazine in vivo. A possible mechanism of action as a carcinogen. J Natl.Cancer Inst. 1981;67(3):613-618.

Chlebowski, R. T., Heber, D., Richardson, B., and Block, J. B. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. Cancer Res. 1984;44(2):857-861.

Cameron, I. L. Effect of total parenteral nutrition on tumor-host responses in rats. Cancer Treat.Rep 1981;65 Suppl 5:93-99.

Gold, J. Anabolic profiles in late-stage cancer patients responsive to hydrazine sulfate. Nutr.Cancer 1981;3(1):13-19.

Bhide, S. V. Anticancer properties of isoniazid & hydrazine-sulphate. Indian J Exp Biol 1978;16(8):926-928.

Kulkarni, S. G. and Nawaz, M. Acute hepatic encephalopathy following hydrazine - hydrate poisoning. J Assoc Physicians India 1982;30(3):171-172.

Filov, V. A., Gershanovich, M. L., Danova, L. A., and Ivin, B. A. Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS) in the advanced cancer patients. Invest New Drugs 1995;13(1):89-97.

Filov, V. A., Gershanovich, M. L., Ivin, B. A., Danova, L. A., Gurchin, F. A., Naryshkin, A. G., Leshchinskii, V. I., Zemskaia, A. G., Nikiforov, B. M., and Breivis, P. V. [Therapy of primary brain tumors with segidrin]. Vopr.Onkol. 1994;40(7-12):332-336.

Tayek, J. A., Sutter, L., Manglik, S., Lillington, L. B., Grosvenor, M., and Chlebowski, R. T. Altered metabolism and mortality in patients with colon cancer receiving chemotherapy. Am.J.Med.Sci. 1995;310(2):48-55.

Suzuki, H., Tominaga, T., Mizuno, H., Kouno, M., Suzuki, M., Kato, Y., Sato, A., Okabe, K., Uchikoshi, T., Maezono, K., and . Ethanol and hydrazine sulfate induced chronic hepatic injury in rats: the curative effect of administration of glucogenic amino acids. Alcohol Alcohol Suppl 1993;1A:111-117.

Fitzgerald B.E. and Shank, R. C. Methylation status of DNA cytosine during the course of induction of liver cancer in hamsters by hydrazine sulfate. Carcinogenesis 1996;17(12):2703-2709.

Zheng, H. and Shank, R. C. Changes in methyl-sensitive restriction sites of liver DNA from hamsters chronically exposed to hydrazine sulfate. Carcinogenesis 1996;17(12):2711-2717.

Danova, L. A., Kondrat'ev, V. B., Gershanovich, M. L., and Filov, V. A. [Results of the use of hydrazine sulfate in lymphogranulomatosis]. Ter.Arkh. 1977;49(8):45-47.

Kamradt, J. M. and Pienta, K. J. The effect of hydrazine sulfate on prostate cancer growth. Oncol.Rep. 1998;5(4):919-921.

Bhide, S. V., D'Souza, R. A., Sawai, M. M., and Ranadive, K. J. Lung tumour incidence in mice treated with hydrazine sulphate. Int J Cancer 10-15-1976;18(4):530-535.

Gold J. Use of hydrazine sulfate in advanced cancer patients: preliminary results [abstact]. Proc Am Assoc Cancer Res 1974;15:83.

Chlebowski RT, Heber D, Richardson B, and et al. Association between improved carbohydrate metabolism and weight maintenance in hydrazine sulfate treated patients with cancer cachexia [abstract]. Proc Am Soc Clin Oncology 1983;2:95.

Strum SB, Bierman HR, and Thompson R. Hydrazine sulfate in patients with neoplasia [abstract]. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 1975;16:243.

Gold J. Hydrazine sulfate and cancer cachexia. Nutrition and Cancer 1979;1(4):4-9.

Beer DT and Schaffner F. Fatal jaundice after administration of beta-phenylisopropylhydrazine. JAMA 1959;171(7):887-889.

Toth B. A review of cancer risk associated with human exposure to hydrazines. Intern J Oncol 1994;4:231-239.

Nadel MV. Contrary to allegation, NIH hydrazine sulfate studies were not flawed. Report to the Chairman and Ranking Minority Member, Human Resources and Intergovernmental Relations Subcommittee, House Committee on Government Reform and Oversight 1995;1-24.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.